Announcement PDF Investor Webinar Presentation Melbourne, Australia, February 8, 2024: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief Executive Officer, Steven Lydeamore will be presenting at the Monsoon Communications Investor function on Thursday, 8th February in Sydney, Australia. A copy of the presentation being made is included below. Authorised for release by the Board of Immuron Limited. COMPANY CONTACT: Steven Lydeamore Chief Executive Officer Ph: +61 (0)3 9824 5254 info@immuron.com - - - END - - - About Travelan® Travelan® is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting traveller’s diarrhoea, a digestive tract disorder that is commonly caused by pathogenic bacteria and the toxins they produce. Travelan® is a highly purified tabletised preparation of hyperimmune bovine antibodies and other factors, which when taken with meals bind to diarrhoea-causing bacteria and prevent colonisation and the pathology associated with traveller’s diarrhoea. In Australia, Travelan® is a listed medicine on the Australian Register for Therapeutic Goods (AUST L 106709) and is indicated to reduce the risk of Traveller’s Diarrhoea, reduce the risk of minor gastrointestinal disorders and is antimicrobial. In Canada, Travelan® is a licensed natural health product (NPN 80046016) and is indicated to reduce the risk of Traveller’s Diarrhoea. In the U.S., Travelan® is sold as a dietary supplement for digestive tract protection. About Traveller’s Diarrhoea Traveller’s Diarrhoea is a gastrointestinal infection with symptoms that include loose, watery (and occasionally bloody) stools, abdominal cramping, bloating, and fever, Enteropathogenic bacteria are responsible for most cases, with enterotoxigenic Escherichia coli (ETEC) playing a dominant causative role. Campylobacter spp. are also responsible for a significant proportion of cases. The more serious infections with Salmonella spp. the bacillary dysentery organisms belonging to Shigella spp. and Vibrio spp. (the causative agent of cholera) are often confused with Traveller’s Diarrhoea as they may be contracted while travelling and initial symptoms are often indistinguishable. About Immuron Immuron Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercialising orally delivered targeted polyclonal antibodies for the treatment of infectious diseases. For more information visit: http://www.immuron.com FORWARD-LOOKING STATEMENTS: This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. INVESTOR PRESENTATION M O N S O O N C O M M U N I C AT I O N S 8 FEBRUARY, 2024 S t e v e n Ly d e a m o r e - C E O NASDAQ: IMRN ASX: IMC 1 SAFE HARBOR STATEMENT C e r ta i n state m e n t s m a d e i n t h i s p re s e nta t i o n a re fo r wa rd - l o o k i n g state m e n t s a n d a re b a s e d o n I m m u ro n ’s c u r re nt ex p e c tat i o n s , e st i m ate s a n d p ro j e c t i o n s . Wo rd s s u c h a s “a nt i c i p a t e s ,” “ex p e c t s ,” “ i nte n d s ,” “ p l a n s ,” “ b e l i e ve s ,” “s e e ks ,” “e st i m a te s ,” “g u i d a n c e ” a n d s i m i l a r ex p re s s i o n s a re i nte n d e d to i d e nt i f y fo r wa rd - l o o k i n g state m e n t s . A l t h o u g h I m m u ro n b e l i e v e s t h e fo r wa rd - l o o k i n g state m e n t s a re b a s e d o n re a s o n a b l e a s s u m p t i o n s , t h ey a re s u b j e c t to c e r ta i n r i s ks a n d u n c e r ta i n t i e s , s o m e o f w h i c h a re b eyo n d I m m u ro n ’s c o nt ro l , i n c l u d i n g t h o s e r i s ks o r u n c e r ta i n t i e s i n h e re n t i n t h e p ro c e s s o f b o t h d e ve l o p i n g a n d c o m m e rc i a l i z i n g te c h n o l o g y. A s a re s u l t , a c t u a l re s u l t s c o u l d m ate r i a l l y d i ffe r f ro m t h o s e ex p re s s e d o r fo re ca ste d i n t h e fo r wa rd - l o o k i n g state m e n t s . T h e fo r wa rd - l o o k i n g state m e n t s m a d e i n t h i s p re s e n ta t i o n re l ate o n l y to e ve nt s a s o f t h e d ate o n w h i c h t h e state m e n t s a re m a d e . I m m u ro n w i l l n o t u n d e r ta ke a ny o b l i gat i o n to re l e a s e p u b l i c l y a ny re v i s i o n s o r u p d ate s to t h e s e fo r wa rd - l o o k i n g state m e n t s to ref l e c t e ve nt s , c i rc u m sta n c e s o r u n a nt i c i p a te d e ve nt s o c c u r r i n g a f te r t h e d ate o f t h i s p re s e nta t i o n exc e p t a s re q u i re d b y l aw o r b y a ny a p p ro p r i a te re g u l ato r y a u t h o r i t y. F Y 2 0 2 4 re s u l t s i n t h i s p re s e nta t i o n a re s u b j e c t to a u d i t re v i e w. 2 REVENUE GENERATING WITH STRONG PIPELINE Immuron Ltd (NASDAQ:IMRN) (ASX:IMC) is a globally integrated biopharmaceutical company focused on developing, and commercialising, oral immunotherapeutics for the treatment of gut mediated diseases Financial Snapshot Shares on Issue Total Options Last Traded Price Market Cap. Cash & Cash Equivalents Sales Revenue 30-Jun-23 31-Dec-23 227,798,346 12,879,720 IMC: A$0.075 IMC: A$17.1m 227,798,346 15,568,559 IMC: A$0.077 IMC: A$17.5m A$17.2m A$1.8m H1, FY24 A$2.4m 3 REVENUE GENERATING WITH STRONG PIPELINE Immuron Ltd (NASDAQ:IMRN) (ASX:IMC) is a globally integrated biopharmaceutical company focused on developing, and commercialising, oral immunotherapeutics for the treatment of gut mediated diseases Pipeline Snapshot 30-Jun-23 31-Dec-23 Travelan (IMM-124E) Phase 2 Traveller’s Diarrhoea Travelan® (IMM-124E) – Phase 4 Traveller’s Diarrhoea Initiated IMM-124E ETEC2 CHIM3 clinical trial Completion of In-patient phase ETEC2 CHIM3 clinical trial USU4 P2TD IMM-124E field clinical trial recruited 35% of 868 participants Recruited 50% of 868 participants CampETEC – Phase 2 Campylobacteriosis FDA IND1 approved (Clinical Hold released) Completion of In-patient phase Campylobacter CHIM3 clinical trial IMM-529 – Phase 2 Clostridioides Difficile Completed 600 mg solid dose active formulation development Completion of IMM-529 drug substance manufacture by CSIRO 1. Investigational New Drug; 2. Enterotoxigenic E.coli; 3. controlled human infection model; 4. Uniformed Health Services University of the Health Sciences 4 DISTRIBUTION CAPABILITY Australia USA Shandex Canada Ontario, Canada Distributes to all provinces of Canada Retail Pharmacy B2B Established E-commerce Developing Immuron Limited Vancouver, BC, Canada Key Commentary Australia • Retail network includes over 3,500 pharmacies • Online sales of both Travelan® and Protectyn® • Protectyn® is distributed by Osborne Health Supplies USA • Travelan® is sold to travel medicine clinics and on our own amazon.com shopfront (launched July 2023) • Re-entry into retail pharmacies in USA being explored in FY24 Canada • We are relaunching 1Q2024 International • We are evaluating options to enter international markets through distributors RJW Logistics Immuron Inc. Chicago, USA Distributes to all states of USA New York, USA Immuron Limited Melbourne, Australia Distributes to all states of Australia and to distributors in USA and Canada 5 Traveller’s Diarrhoea (TD) STRONG SALES GROWTH IN A BILLION DOLLAR MARKET 3 Market is large and growing ~7% 3 CAGR Industry tailwinds Travel picking up significantly following COVID lockdowns Frequent 30% - 70% of travelers experience TD 4 Net Sales FY23: A$1.16 million 1HFY24: A$1.85 million 132% higher than prepandemic period 1HFY20 Net Sales FY23: A$0.64 million 1HFY24: A$0.48 million 6% lower than prepandemic period 1HFY20 Australia Short term resident returns in Oct 23 were 47% higher than Oct 22 1 USA Total departures Sep 23 were 17% higher than Sep 22 2 Chief Commercial Officer has 20+ year’s experience with local and global (Asia, UK) commercial leadership roles with GSK and P&G $83m $50m Based on US annual travel numbers and a penetration rate of 15%, the market potential is estimated at $83m 5 Based on EU travel numbers and a penetration rate of 15%, the market potential is estimated at $50m 5 1. https://www.abs.gov.au/statistics/industry/tourism-and-transport/overseas-arrivals-and-departures-australia/latest-release 2. https://www.trade.gov/sites/default/files/2023-09/US-Outbound-to-World-Regions.xlsx 3. https://www.transparencymarketresearch.com/travelers-diarrhea-market.html 4. Centers for Disease Control and Prevention Yellow Book 5. IMC Company Report - Travelan Market Analysis 2019 6 TECHNOLOGY PLATFORM FOR GUT MEDIATED DISEASES Bovine colostrum is the first milk of cows after calving. It is rich in immunoglobulins, lactoferrin, lysozyme, lactoperoxidase, growth factors and bioactive peptides. Colostrum has higher levels of protein, fat, vitamins, and minerals when compared to milk. This enables full development of the newborn calf in addition to immunity against several pathogens.* Immuron’s proprietary technology platform combines the natural human nutrition & health benefits of bovine colostrum with a novel class of specifically targeted oral polyclonal antibodies that offer delivery within the gastrointestinal (“GI”) tract and can be used to target viruses or bacteria and neutralize the toxins they produce at mucosal surfaces. STEP 1 Development of Highly Specific Vaccines STEP 2 Isolation of Hyperimmune antibody-rich bovine colostrum * Gomes et. al., NFS Journal, Volume 25, November 2021, pages 111, https://doi.org/10.1016/j.nfs.2021.10.001 STEP 3 Oral Antimicrobial therapeutics without drawbacks of antibiotics FINAL PRODUCT Toxin Neutralization + Clearance of targeted gut pathogens ✓ Reduce occurrence and reduce/relieve diarrhoea ✓ Reduce/relieve abdominal cramping ✓ Reduce/relieve gastrointestinal pain ✓ Assists repair of gastrointestinal/gut wall lining ✓ Enhance/promote immune defence ✓ Enhance/promote health liver function Australian Permitted indications; these statements have not been evaluated by the Food and Drug Administration (FDA) 7 STRONG PIPELINE WITH NEAR TERM MILESTONES Immuron’s Clinical Programs Compound or brand name Indication IMM-124E Travelan® Traveler’s Diarrhea ETEC challenge IMM-529 Clostridioides difficile Infection & Recurrence Phase I Phase II Phase III Market Our Partners’ Clinical Programs Compound or brand name Travelan® CampETEC Partner Phase I Phase II Phase III Market Uniformed Services University Naval Medical Research Command Further information on the clinical programs can be found on slide 8 8 NEAR TERM MILESTONES ANTICIPATED TO DRIVE VALUE 2H 2022 1H 2023 2H 2023 FDA IND1 approved for • single daily dose IMM• 124E ETEC2 CHIM3 clinical trial IRB Approval4 • Initiated IMM-124E ETEC2 • CHIM3 clinical trial 100% of patients enrolled • Completion of In-patient phase ETEC2 CHIM3 clinical trial Topline results for IMM- • 124E ETEC2 clinical trial Clinical Study Report • Submitted Response • Letter to FDA Clinical Hold • Immuron sponsored Toxicology study completed Toxicology Study Report FDA IND1 approved (Clinical Hold released) • Institutional Review • 5 Board approval of NMRC CampETEC Campylobacter CHIM3 clinical trial protocol Initiated IMM-124E Campylobacter CHIM3 clinical trial IMM-529 cGMP • manufacture ~50% of 868 participants • recruited • Completion of Inpatient phase CampETEC Campylobacter CHIM3 clinical trial • Topline results for CampETEC Campylobacter CHIM3 clinical trial IMM-529 (CDI)7 PreIND1 submission Completion of enrollment Completion of inpatient phase • FDA meeting • Topline results • CampETEC • • • Travelan® 2H 2024 • Travelan® IMM-529 1H 2024 600 mg solid dose active formulation development USU6 P2TD IMM-124E field clinical trial recruitment commencement • • Completed; 1. Investigational New Drug; 2. Enterotoxigenic E.coli; 3. controlled human infection model; 4. Institutional Review Board; 5. Naval Medical Research Command; 6. Uniformed Health Services University of the Health Sciences; 7. Clostridioides Difficile 9 SCIENTIFIC REFERENCES Travelan® (IMM-124E) Travelan® has been shown to reduce both the incidence and severity of ETEC-induced diarrhea in up to 90% of volunteers Scandinavian Journal of Gastroenterology, 46:7-8, 862-868, DOI: 10.3109/00365521.2011.574726 Clinical Evaluation of Travelan® an Oral Prophylactic for Prevention of Travelers’ Diarrhea in Active Duty Military Service Assigned Abroad. Military Health System Research Symposium 14-17 Aug 2023_Abstract 1 Travelan as a broad Spectrum anti-bacterial Immuron Limited, 29 April, 2011 Travelan® demonstrates broad reactivity to Vibrio cholera strains from Southeast Asia indicating broad potential for prevention of traveler’s diarrhea US Department of Defense, Armed Forces Research Institute of Medical Sciences (AFRIM), 4 September, 2019 Travelan® prevented clinical shigellosis (bacillary dysentery) in 75% of Travelan® treated animals compared to placebo and demonstrated a significant clinical benefit US Department of Defense, Armed Forces Research Institute of Medical Sciences (AFRIM), 5 September, 2018 Travelan® able to bind and was reactive to 60 clinical isolates of each bacteria, Campylobacter, ETEC, and Shigella US Department of Defense, Armed Forces Research Institute of Medical Sciences (AFRIM), 30 January, 2017 Bioactivity and efficacy of a hyperimmune bovine colostrum product- Travelan, against shigellosis in a nonHuman primate model (Macaca mulatta) Islam D, Ruamsap N, Imerbsin R, Khanijou P, Gonwong S, Wegner MD, et al. (2023) Bioactivity and efficacy of a hyperimmune bovine colostrum product- Travelan, against shigellosis in a non-Human primate model (Macaca mulatta). PLoS ONE 18(12): e0294021. Bioactive Immune Components of Travelan® Clin Vaccine Immunol 24:e00186-16. https://doi.org/10.1128/CVI.00186-16 Hyperimmune bovine colostrum containing lipopolysaccharide antibodies (IMM-124E) has a non-detrimental effect on gut microbial communities in unchallenged mice Infect Immun. 2023 Nov; 91(11): e00097-23. Administration of the Hyper-immune Bovine Colostrum Extract IMM-124E Ameliorates Experimental Murine Colitis Journal of Crohn's and Colitis, Volume 13, Issue 6, June 2019, Pages 785–797, https://doi.org/10.1093/ecco-jcc/jjy213 IMM-529 Bovine antibodies targeting primary and recurrent Clostridium difficile disease are a potent antibiotic alternative Sci Rep 7, 3665 (2017). https://doi.org/10.1038/s41598-017-03982-5 10 STEVEN LYDEAMORE CHIEF EXECUTIVE OFFICER IMMURON LIMITED CONTACT INFORMATION: EMAIL: STEVE@IMMURON.COM PHONE: AUSTRALIA: +61 438 027 172 11